Advanced search
Publication Cover
Current Medical Research and Opinion Volume 27, 2011 - Issue 5
Submit an article Journal homepage
419
Views
12
CrossRef citations to date
0
Altmetric
Original Article

Effect of fesoterodine 4 mg on bladder diary and patient-reported outcomes during the first week of treatment in subjects with overactive bladder

Jacques Corcos Department of Urology, Jewish General Hospital, Montreal, QC, CanadaCorrespondence[email protected]
,
Javier C. Angulo Servicio de Urología, Hospital Universitario de Getafe, Madrid, Spain
,
Alan D. Garely Department of Obstetrics, Gynecology and Reproductive Science, Mount Sinai School of Medicine, New York, NY, USA
,
Martin Carlsson Pfizer Inc, New York, NY, USA
,
Jason Gong Pfizer Inc, New York, NY, USA
,
Zhonghong Guan Pfizer Inc, New York, NY, USA
& on behalf of the Fesoterodine Assessment and Comparison Versus Tolterodine (FACT) Study Group show all
Pages 1059-1065 | Accepted 17 Feb 2011, Published online: 23 Mar 2011

References

  • Andersson KE, Chapple CR, Cardozo L, et al. Pharmacological treatment of overactive bladder: report from the International Consultation on Incontinence. Curr Opin Urol 2009;19:380-94
  • Cawello W, Auer S, Hammes W, et al. Multiple dose pharmacokinetics of fesoterodine in human subjects. Arch Pharmacol 2002;365:R110
  • Michel MC. Fesoterodine: a novel muscarinic receptor antagonist for the treatment of overactive bladder syndrome. Expert Opin Pharmacother 2008;9:1787-96
  • Malhotra B, Guan Z, Wood N, et al. Pharmacokinetic profile of fesoterodine. Int J Clin Pharmacol Ther 2008;46:556-63
  • Toviaz® (fesoterodine fumarate). Full Prescribing Information, Pfizer Inc, New York, NY, 2007
  • Chapple C, Van Kerrebroeck P, Tubaro A, et al. Clinical efficacy, safety, and tolerability of once-daily fesoterodine in subjects with overactive bladder. Eur Urol 2007;52:1204-12
  • Nitti V, Dmochowski R, Sand P, et al. Efficacy, safety, and tolerability of fesoterodine in subjects with overactive bladder. J Urol 2007;178:2488-94
  • Kelleher CJ, Tubaro A, Wang JT, et al. Impact of fesoterodine on quality of life: pooled data from two randomized trials. BJU Int 2008;102:56-61
  • Wyndaele JJ, Goldfischer ER, Morrow JD, et al. Effects of flexible-dose fesoterodine on overactive bladder symptoms and treatment satisfaction: an open-label study. Int J Clin Pract 2009;63:560-7
  • Dmochowski RR, Peters KM, Morrow JD, et al. Randomized, double-blind, placebo-controlled trial of flexible-dose fesoterodine in subjects with overactive bladder. Urology 2010;75:62-8
  • Herschorn S, Swift S, Guan Z, et al. Comparison of fesoterodine and tolterodine extended release for the treatment of overactive bladder: a head-to-head placebo-controlled trial. BJU Int 2010;105:58-66
  • Coyne KS, Sexton CC, Irwin DE, et al. The impact of overactive bladder, incontinence and other lower urinary tract symptoms on quality of life, work productivity, sexuality and emotional well-being in men and women: results from the EPIC study. BJU Int 2008;101:1388-95
  • Liberman JN, Hunt TL, Stewart WF, et al. Health-related quality of life among adults with symptoms of overactive bladder: results from a U.S. community-based survey. Urology 2001;57:1044-50
  • Herschorn S, Heesakkers J, Castro-Diaz D, et al. Effects of tolterodine extended release on patient perception of bladder condition and overactive bladder symptoms. Curr Med Res Opin 2008;24:3513-21
  • Siami P, Seidman LS, Lama D. A multicenter, prospective, open-label study of tolterodine extended-release 4 mg for overactive bladder: the speed of onset of therapeutic assessment trial (STAT). Clin Ther 2002;24:616-28
  • Sussman DO, Kraus SR, Carlsson M, et al. Onset of efficacy of tolterodine extended release in patients with overactive bladder. Curr Med Res Opin 2007;23:777-81
  • Zinner N, Gittelman M, Harris R, et al. Trospium chloride improves overactive bladder symptoms: a multicenter phase III trial. J Urol 2004;171:2311-15
  • Rudy D, Cline K, Harris R, et al. Time to onset of improvement in symptoms of overactive bladder using antimuscarinic treatment. BJU Int 2006;97:540-6
  • Cardozo L, Hessdorfer E, Milani R, et al. Solifenacin in the treatment of urgency and other symptoms of overactive bladder: results from a randomized, double-blind, placebo-controlled, rising-dose trial. BJU Int 2008;102:1120-7
  • Goldman HB, Morrow JD, Gong J, et al. Early onset of fesoterodine efficacy in subjects with overactive bladder. BJU Int 2010;107:598-602
  • Coyne KS, Margolis MK, Hsieh R, et al. Validation of the urinary sensation scale (USS). Neurourol Urodyn 2011 [Epub ahead of print] doi: 10.1002/nau.21005
  • Coyne KS, Matza LS, Kopp Z, et al. The validation of the Patient Perception of Bladder Condition (PPBC): a single-item global measure for patients with overactive bladder. Eur Urol 2006;49:1079-86
  • Cardozo L, Coyne KS, Versi E. Validation of the Urgency Perception Scale. BJU Int 2005;95:591-6
  • Van Elteren PH. On the combination of independent two-sample tests of Wilcoxon. Bulletin of the International Statistical Institute 1960;37:351-61
  • Zhao YD. Sample size estimation for the van Elteren test–a stratified Wilcoxon-Mann-Whitney test. Stat Med 2006;25:2675-87
  • Herschorn S, Jones JS, Oelke M, et al. Efficacy and tolerability of fesoterodine in men with overactive bladder: a pooled analysis of 2 phase III studies. Urology 2010;75:1149-55
  • Sand PK, Morrow JD, Bavendam T, et al. Efficacy and tolerability of fesoterodine in women with overactive bladder. Int Urogynecol J Pelvic Floor Dysfunct 2009;20:827-35

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.